Prospective T1 mapping to assess gadolinium retention in brain after intrathecal gadobutrol

G Ringstad, LM Valnes, SAS Vatnehol, AH Pripp… - Neuroradiology, 2023 - Springer
Purpose A possible pathway behind gadolinium retention in brain is leakage of contrast
agents from blood to cerebrospinal fluid and entry into brain along perivascular (glymphatic) …

Repeated intravenous administration of gadobutrol does not lead to increased signal intensity on unenhanced T1-weighted images—a voxel-based whole brain …

S Langner, ML Kromrey, JP Kuehn, M Grothe… - European …, 2017 - Springer
Objectives To identify a possible association between repeated intravenous administration
of gadobutrol and increased signal intensity in the grey and white matter using voxel-based …

MRI brain signal intensity and relaxation times in individuals with prior exposure to gadobutrol

M Saake, A Schmidle, M Kopp, J Hanspach, T Hepp… - Radiology, 2019 - pubs.rsna.org
Purpose To perform follow-up brain MRI in volunteer participants who had previously
received multiple doses of gadobutrol and to assess for changes in signal intensities and …

Brain deposition of gadobutrol in children—a cross-sectional and longitudinal MRI T1 mapping study

D Gräfe, SH Simion, M Rosolowski… - European …, 2023 - Springer
Objectives Depositions of linear gadolinium-based MRI contrast agents are readily visible in
T1-weighted MRIs of certain brain regions in both adults and children. Macrocyclic contrast …

Accumulation of gadolinium in human cerebrospinal fluid after gadobutrol-enhanced MR imaging: a prospective observational cohort study

AK Nehra, RJ McDonald, AM Bluhm, TM Gunderson… - Radiology, 2018 - pubs.rsna.org
Purpose To determine whether gadolinium accumulates within cerebrospinal fluid (CSF) in
patients recently exposed to the macrocyclic agent gadobutrol and identify factors that may …

Evaluation of gadolinium retention after serial administrations of a macrocyclic gadolinium-based contrast agent (gadobutrol): a single-institution experience with 189 …

RE Yoo, CH Sohn, KM Kang, TJ Yun… - Investigative …, 2018 - journals.lww.com
Objective There has been controversy as to whether gadobutrol, one of the widely used
macrocyclic gadolinium-based contrast agents, can lead to gadolinium retention after serial …

Intravenous injection of gadobutrol in an epidemiological study group did not lead to a difference in relative signal intensities of certain brain structures after 5 years

ML Kromrey, KR Liedtke, T Ittermann, S Langner… - European …, 2017 - Springer
Purpose To investigate if application of macrocyclic gadolinium-based contrast agents in
volunteers is associated with neuronal deposition detected by magnetic resonance imaging …

Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities

RJ McDonald, JS McDonald, DF Kallmes, ME Jentoft… - Radiology, 2017 - pubs.rsna.org
Purpose To determine whether gadolinium deposits in neural tissues of patients with
intracranial abnormalities following intravenous gadolinium-based contrast agent (GBCA) …

Gadolinium deposition within the paediatric brain: no increased intrinsic T1-weighted signal intensity within the dentate nucleus following the administration of a …

JR Young, J Qiao, I Orosz, N Salamon, MA Franke… - European …, 2018 - Springer
Objectives To determine whether repeated administration of the macrocyclic gadolinium-
based contrast agent (GBCA) gadobutrol in children is associated with T1-weighted …

Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents—current status

D Stojanov, A Aracki-Trenkic, D Benedeto-Stojanov - Neuroradiology, 2016 - Springer
Introduction Gadolinium-based contrast agents (GBCAs) have been used clinically since
1988 for contrast-enhanced magnetic resonance imaging (CE-MRI). Generally, GBCAs are …